LLY

971.94

-1.55%↓

JNJ

220.82

-1.05%↓

ABBV

202.3

-0.97%↓

UNH

367.04

-0.29%↓

AZN

181.19

-1.38%↓

LLY

971.94

-1.55%↓

JNJ

220.82

-1.05%↓

ABBV

202.3

-0.97%↓

UNH

367.04

-0.29%↓

AZN

181.19

-1.38%↓

LLY

971.94

-1.55%↓

JNJ

220.82

-1.05%↓

ABBV

202.3

-0.97%↓

UNH

367.04

-0.29%↓

AZN

181.19

-1.38%↓

LLY

971.94

-1.55%↓

JNJ

220.82

-1.05%↓

ABBV

202.3

-0.97%↓

UNH

367.04

-0.29%↓

AZN

181.19

-1.38%↓

LLY

971.94

-1.55%↓

JNJ

220.82

-1.05%↓

ABBV

202.3

-0.97%↓

UNH

367.04

-0.29%↓

AZN

181.19

-1.38%↓

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Open

1.21

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.2

Max

1.25

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.7M -24M
EPS	-0.354
Angestellte	49
EBITDA	-5.3M -28M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+124.37% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-7.4M 74M
Vorheriger Eröffnungskurs	1.21
Vorheriger Schlusskurs	1.21

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Mai 2026, 23:41 UTC

Ergebnisse

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6. Mai 2026, 21:40 UTC

Ergebnisse

Nutrien Logs Higher Profit, Sales Growth in 1Q

6. Mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6. Mai 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6. Mai 2026, 23:13 UTC

Ergebnisse

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6. Mai 2026, 23:13 UTC

Ergebnisse

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6. Mai 2026, 23:12 UTC

Ergebnisse

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6. Mai 2026, 23:11 UTC

Ergebnisse

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6. Mai 2026, 23:07 UTC

Ergebnisse

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6. Mai 2026, 23:06 UTC

Ergebnisse

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6. Mai 2026, 23:06 UTC

Ergebnisse

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6. Mai 2026, 23:05 UTC

Ergebnisse

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6. Mai 2026, 23:04 UTC

Ergebnisse

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6. Mai 2026, 22:50 UTC

Ergebnisse

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6. Mai 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6. Mai 2026, 22:11 UTC

Ergebnisse

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6. Mai 2026, 22:11 UTC

Ergebnisse

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6. Mai 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6. Mai 2026, 21:58 UTC

Ergebnisse

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. Mai 2026, 21:47 UTC

Market Talk

Ergebnisse

Costco Posts 13% Sales Growth in April -- Market Talk

6. Mai 2026, 21:46 UTC

Ergebnisse

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6. Mai 2026, 21:40 UTC

Ergebnisse

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. Mai 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6. Mai 2026, 21:32 UTC

Heiße Aktien

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6. Mai 2026, 21:29 UTC

Ergebnisse

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

124.37% Vorteil

12-Monats-Prognose

Durchschnitt 2.67 USD 124.37%

Hoch 3 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.